Beware copycat probes after Sanofi generics case
This article was originally published in Scrip
Executive Summary
This week's €40.6 million fine against Sanofi could presage further investigations into the legality of techniques used by pharmaceutical companies to protect their franchises from generic competition. However, with the lack of previous cases addressing the specific abuses brought to light in the Sanofi case, the limits of acceptable practice may be hard to define, and the need for companies to tread carefully is complicated by the difficulty in pinning down future interpretations of legality.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.